<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03482648</url>
  </required_header>
  <id_info>
    <org_study_id>BBT401-UC-US01</org_study_id>
    <nct_id>NCT03482648</nct_id>
  </id_info>
  <brief_title>First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Novel Oral Peptide BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bridge Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCRN Research, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bridge Biotherapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is the first-in-human study of BBT-401-1S. The purpose of this phase 1
      study is to assess the safety and tolerability of single and multiple ascending oral doses of
      BBT-401-1S in healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2018</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>7 days after the last dose</time_frame>
    <description>To assess the safety and tolerability of single and multiple ascending oral doses of BBT-401-1S in healthy adult subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>72 hours after the last dose</time_frame>
    <description>To assess Cmax of single and multiple ascending oral doses of BBT-401-1S in healthy adult subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>72 hours after the last dose</time_frame>
    <description>To assess AUC of single and multiple ascending oral doses of BBT-401-1S in healthy adult subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) under fed conditions</measure>
    <time_frame>72 hours after the last dose</time_frame>
    <description>To assess Cmax of single oral dose under fed conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) under fed conditions</measure>
    <time_frame>72 hours after the last dose</time_frame>
    <description>To assess AUC of single oral dose under fed conditions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Single Ascending Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBT-401-1S, Single dose</intervention_name>
    <description>Single dose of BBT-401-1S, 7 dose levels, oral capsule</description>
    <arm_group_label>Single Ascending Doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBT-401-1S, Multiple doses</intervention_name>
    <description>Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule</description>
    <arm_group_label>Multiple Ascending Doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to BBT-401-1S, oral capsule</description>
    <arm_group_label>Single Ascending Doses</arm_group_label>
    <arm_group_label>Multiple Ascending Doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult male and/or female (non-childbearing potential only), 19 to 55 years of
             age, inclusive, at screening.

          2. Continuous non-smoker who has not used nicotine-containing products for at least 3
             months prior to the first dose and throughout the study.

          3. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 (kg/m2) at screening and weight ≥ 50 kg at
             screening.

          4. Medically healthy with no clinically significant medical history, physical
             examination, laboratory profiles, vital signs or ECGs, as deemed by the PI.

          5. No clinically significant history or presence of ECG findings as judged by the PI or
             qualified designee at screening and check-in.

          6. For a female, must be of non-childbearing potential and therefore must have undergone
             one of the following sterilization procedures, at least 6 months prior to the first
             dose:

               1. hysteroscopic sterilization;

               2. bilateral tubal ligation or bilateral salpingectomy;

               3. hysterectomy;

               4. bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year
                  prior to the first dose and follicle-stimulating hormone (FSH) serum levels
                  consistent with postmenopausal status as per PI judgment.

          7. A non-vasectomized, male subject must agree to use a condom with spermicide or abstain
             from sexual intercourse during the study until 90 days beyond the last dose of study
             drug. (No restrictions are required for a vasectomized male provided his vasectomy has
             been performed 4 months or more prior to the first dose of study drug. A male who has
             been vasectomized less than 4 months prior to the first dose must follow the same
             restrictions as a non-vasectomized male).

          8. If male, must agree to not donate sperm from the first dose until 90 days after
             dosing.

          9. Must have the ability to understand and sign a written informed consent form, which
             must be obtained prior to initiation of study procedures.

        Exclusion Criteria:

          1. Subject is mentally or legally incapacitated or has significant emotional problems at
             the time of the screening visit or expected during the conduct of the study.

          2. History or presence of clinically significant medical or psychiatric condition or
             disease in the opinion of the PI.

          3. History of any illness that, in the opinion of the PI, might confound the results of
             the study or poses an additional risk to the subject by their participation in the
             study.

          4. History or presence of alcoholism or drug abuse within the past 2 years prior to the
             first dose or regular alcohol consumption within 6 months prior to the first dose with
             an average weekly intake of greater than 21 glasses/units per week for males or 14
             glasses/units per week for females, with one unit = 150 mL of wine or 360 mL of beer
             or 45 mL of 45% alcohol.

          5. History or presence of hypersensitivity or idiosyncratic reaction to the study drug(s)
             or related compounds.

          6. History of sensitivity to heparin or heparin-induced thrombocytopenia.

          7. Active or latent tuberculosis.

          8. Estimated creatinine clearance &lt;80 mL/min at screening.

          9. Liver function tests (serum ALT, AST, alkaline phosphatase) and serum bilirubin (total
             and direct) &gt; ULN.

         10. Absolute neutrophil count &lt; 1500 cells/mm3.

         11. White blood cell count &lt; 3500 cells/mm3.

         12. Haemoglobin levels &lt; 0.5 mg/dL below the lower limit of normal.

         13. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.

         14. Female subjects of childbearing potential.

         15. Female subjects who are pregnant or lactating.

         16. Positive urine drug or alcohol results at screening or check-in.

         17. Positive urine cotinine at screening.

         18. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg), or hepatitis C antibodies (HCV).

         19. Unable to refrain from or anticipates the use of any drug, including prescription and
             non-prescription medications, herbal remedies, or vitamin supplements beginning
             approximately 14 days prior to the first dose and throughout the study.. Hormone
             replacement therapy will not be allowed. After first dosing, acetaminophen (up to 2 g
             per 24 hours) may be administered at the discretion of the PI or designee.

         20. Has been on a diet incompatible with the on-study diet, in the opinion of the PI,
             within the 28 days prior to the first dose and throughout the study.

         21. Donation of blood or significant blood loss within 56 days prior to the first dose.

         22. Plasma donation within 7 days prior to the first dose.

         23. Exposure to more than four new chemical entities within 12 months prior to first
             dosing day.

         24. The subject has participated in a clinical trial and has received an investigational
             product within 30 days, or 5 half-lives of the investigational product (whichever is
             longer) of the first dose of study drug in the current study.

         25. Any condition or circumstance, in the opinion of the PI, which may make the subject
             unlikely to complete the study or comply with study procedures and requirements, or
             may pose a risk to the subject's safety.

         26. Subject has recent history (within 2 weeks of Day -1) of less than 1 bowel movement
             every 2 days.

         27. Subject has recent history (within 2 weeks of Day -1) of abnormal bowel movements,
             such as diarrhea, loose stools, or constipation.

             Stage 1 Only:

         28. Is lactose intolerant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GwangHee Lee, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Bridge Biotherapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeong-Hyun Ryou, M.D.,Ph.D.</last_name>
    <phone>82-10-9816-7274</phone>
    <email>Jeong-Hyun.Ryou@Bridgebiorx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pellino-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

